Form D · Other
Naegis Pharmaceuticals Inc.
Vancouver, A1 · CIK 0002021578
Offering snapshot reported May 2, 2024 · SEC filing
- Reported sold
- $351K Offering amount: $351K
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 19, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 2, 2024 | Initial | $350,812 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-512157
U.S. dollar amounts are based on the Bank of Canada average rate of exchange reported on April 19, 2024, which was CDN$1.3748 = USD$1.00.
Source: Form D, filed May 2, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Burgoyne | Director, Executive |
| Philip Davies | Director |
| Julian Gangolli | Director |
| Cameron Groome | Director |
| Michael Liggett | Director |
| Ian Mc Beath | Director, Executive |
Issuer details
Industry: Other (See others in industry)
Address:
999 West Broadway Suite 720
Vancouver, A1, V5Z 1K5
Vancouver, A1, V5Z 1K5